Skip to Content


Active Substance: C1 inhibitor (human)
Common Name: C1 inhibitor (human)
ATC Code: B06AC01
Marketing Authorisation Holder: Shire Services BVBA
Active Substance: C1 inhibitor (human)
Status: Authorised
Authorisation Date: 2011-06-15
Therapeutic Area: Angioedemas, Hereditary
Pharmacotherapeutic Group: Other haematological agents

Therapeutic Indication

Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE).

Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

What is Cinryze?

Cinryze is a powder and solvent that are made up into a solution for injection. It contains the active substance C1 inhibitor (human).

What is Cinryze used for?

Cinryze is used to treat angioedema (swelling) attacks in adults and adolescents aged 12 to 17 years with hereditary angioedema. Patients with hereditary angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain.

Cinryze is also used for the prevention of angioedema attacks that can be triggered by medical, dental or surgical procedures.

Cinryze is also used for routine prevention in patients who have severe and frequent angioedema attacks for which prevention with oral medicines is not adequate or in patients whose attacks are not adequately treated.

The medicine can only be obtained with a prescription.

How is Cinryze used?

Treatment with Cinryze should be started under the supervision of a doctor experienced in treating hereditary angioedema. Cinryze is given as an injection into a vein.

For treatment of angioedema attacks, the patient is given 1,000 Units at the first sign of an angioedema attack. A second dose of 1,000 Units may be given if the patient has not responded adequately after one hour, or sooner for attacks in the larynx (voice box) or if the start of the treatment had been delayed.

For routine prevention, Cinryze is given as 1,000 units every three or four days. The doctor should review the need for routine prevention on a regular basis and can adjust the frequency of the injections according to how the patient is responding. For prevention before a medical, dental or surgical procedure, Cinryze is given as 1,000 units within the 24 hours before the procedure.

The doctor may decide that the caregivers and patients can carry out the injection provided that they have been adequately trained.

How does Cinryze work?

The active substance in Cinryze, human C1 inhibitor, is a protein extracted from human blood.

The C1 inhibitor protein is required to control the ‘complement’ and ‘contact’ systems, collections of proteins in the blood that fight against infection and cause inflammation. Patients with low levels of this protein have excessive activity of these two systems, which leads to the symptoms of angioedema. Cinryze is used to replace the missing C1 inhibitor, correcting the deficiency and helping to prevent or treat angioedema attacks.

How has Cinryze been studied?

In one main study, Cinryze and placebo (a dummy treatment) were used to treat angioedema attacks in 71 patients with hereditary angioedema. The main measure of effectiveness in this study was how long it took for the symptoms to start improving.

A second main study, involving 24 patients from the first study, looked at the number of attacks over 12-week periods when patients were given Cinryze or placebo as prevention. The patients chosen for the second study were those with frequent attacks, at least two attacks per month on average.

The company also provided data on the use of Cinryze in 91 patients to prevent attacks in patients undergoing a medical, surgical or dental procedure.

What benefit has Cinryze shown during the studies?

Cinryze was more effective than placebo in treating and preventing attacks of angioedema. In the first study, over 50% of patients receiving Cinryze had started having improvements two hours into treatment, compared with 33% of patients given placebo. In the second study, the average number of attacks experienced in patients treated with Cinryze was 6.1 over a 12-week period compared with 12.7 for patients on placebo.

Cinryze was also effective in preventing attacks triggered by medical, surgical, or dental procedures with 98% of procedures not triggering an attack within 72 hours.

What is the risk associated with Cinryze?

The only common side effect seen in studies with Cinryze (seen in between 1 and 10 patients in 100) is rash, which is not serious and typically involves the arms, chest, abdomen or the injection site. Allergic reactions may occur. For the full list of all side effects and restrictions with Cinryze, see the package leaflet.

Why has Cinryze been approved?

Based on the evidence from the studies, the CHMP concluded that Cinryze’s benefits are greater than its risks and recommended that it be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Cinryze?

The company that makes Cinryze will ensure that healthcare professionals in all Member States who are expected to prescribe Cinryze are provided with an educational pack instructing them to ensure that caregivers and patients who will administer the medicine at home are properly trained. There will also be a training leaflet for patients that should be kept at home.

In addition, the company will maintain a patient registry to provide further data on long-term safety and the way the medicine is used in practice.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cinryze have also been included in the summary of product characteristics and the package leaflet.

Other information about Cinryze

The European Commission granted a marketing authorisation valid throughout the European Union for Cinryze on 15 June 2011.

For more information about treatment with Cinryze, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.